Cart
sales@molnova.com
CT52923
CAS No. 205256-55-9
CT52923( —— )
Catalog No. M35387 CAS No. 205256-55-9
CT52923 is a selective, orally active antagonist of platelet-derived growth factor receptor (PDGFR), functioning as an ATP-competitive inhibitor.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 30 | In Stock |
|
| 10MG | 38 | In Stock |
|
| 25MG | 78 | In Stock |
|
| 50MG | 124 | In Stock |
|
| 100MG | 188 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameCT52923
-
NoteResearch use only, not for human use.
-
Brief DescriptionCT52923 is a selective, orally active antagonist of platelet-derived growth factor receptor (PDGFR), functioning as an ATP-competitive inhibitor.
-
DescriptionCT52923 is a selective, orally active platelet-derived growth factor receptor (PDGFR) antagonist. CT52923 also is an ATP-competitive inhibitor. CT52923 can be used for the research variety of pathological diseases, including atherosclerosis, glomerulonephritis, liver cirrhosis, pulmonary fibrosis, and cancer.
-
In VitroCell Migration Assay Cell Line:Rat A10 smooth muscle cells Concentration:0.01-30 μM Incubation Time:24 h Result:Inhibited PDGF-induced cell migration with an IC50 of 64 nM.
-
In VivoAnimal Model:Rat carotid artery balloon angioplasty model.Dosage:5, 15, 30, and 50 mg/kg Administration:Oral gavage; twice daily Result:Inhibited PDGF-mediated response to vascular injury.
-
Synonyms——
-
PathwayAngiogenesis
-
TargetPDGFR
-
RecptorPDGFR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number205256-55-9
-
Formula Weight467.54
-
Molecular FormulaC23H25N5O4S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 50 mg/mL (106.94 mM; Ultrasonic (<60°C)
-
SMILESCOc1cc2ncnc(N3CCN(CC3)C(=S)NCc3ccc4OCOc4c3)c2cc1OC
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. J C Yu, et al. Efficacy of the novel selective platelet-derived growth factor receptor antagonist CT52923 on cellular proliferation, migration, and suppression of neointima following vascular injury. J Pharmacol Exp Ther. 2001 Sep;298(3):1172-8.?
molnova catalog
related products
-
Regorafénib N-oxyde ...
Regorafénib N-oxyde M2 is an active metabolite of Regorafenib. Regorafenib is a multi-target inhibitor for VEGFR1/2/3, PDGFRβ, RET, Kit, and Raf-1.
-
Sunitinib
A multi-targeted RTK inhibitor that targets VEGFR2 (Flk-1) and PDGFRβ with Ki of 8 nM and 9 nM respectively.
-
Toceranib
Toceranib phosphate is an orally active inhibitor of tyrosine kinase (RTK) receptor, and it potently inhibits PDGFR, VEGFR, and Kit(with Kis of 5 and 6 nM for PDGFRβ and Flk-1/KDR, respectively), has antitumor and antiangiogenic activity.
